9月16日，健康元盘中下跌2.07%，截至10:33，报12.77元/股，成交1.33亿元，换手率0.56%，总市值 233.62亿元。 截至6月30日，健康元股东户数7.63万，较上期减少4.32%；人均流通股23991股，较上期增加4.52%。 2025年1月-6月，健康元实现营业收入78.98亿元，同比减少4.08%；归母净利润7.85亿元，同比增长 1.10%。 分红方面，健康元A股上市后累计派现39.79亿元。近三年，累计派现10.40亿元。 机构持仓方面，截止2025年6月30日，健康元十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股6837.85万股，相比上期增加1499.69万股。南方中证500ETF（510500）位居第四大流通股 东，持股1627.47万股，相比上期增加194.70万股。创新药（159992）位居第七大流通股东，持股 1030.80万股，相比上期减少378.85万股。 责任编辑：小浪快报 资金流向方面，主力资金净流出1750.91万元，特大单买入399.34万元，占比3.01%，卖出1757.84万元， 占比13.25%；大单买入2612.44万元，占比19. ...

Core Viewpoint - Health元's stock price has experienced fluctuations, with a year-to-date increase of 16.71% but a recent decline of 5.07% over the past five trading days [1] Company Overview - Health元 Pharmaceutical Group Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on December 18, 1992, with its listing date on June 8, 2001 [1] - The company operates as a comprehensive pharmaceutical enterprise, primarily engaged in the research, development, and production of traditional Chinese medicine, health products, and Western medicine [1] - The revenue composition includes: chemical preparations 47.71%, chemical raw materials and intermediates 31.97%, traditional Chinese medicine preparations 10.28%, diagnostic reagents and equipment 4.74%, health food 3.08%, biological products 1.20%, and others 0.86% [1] Financial Performance - For the first half of 2025, Health元 reported operating revenue of 7.898 billion yuan, a year-on-year decrease of 4.08%, while net profit attributable to shareholders increased by 1.10% to 785 million yuan [2] - Since its A-share listing, Health元 has distributed a total of 3.979 billion yuan in dividends, with 1.04 billion yuan distributed in the last three years [3] Shareholder Information - As of June 30, 2025, Health元 had 76,300 shareholders, a decrease of 4.32% from the previous period, with an average of 23,991 circulating shares per person, an increase of 4.52% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder with 68.3785 million shares, an increase of 14.9969 million shares from the previous period [3]

Group 1 - The controlling shareholder of the company, Shenzhen Baiye Yuan Investment Co., Ltd., holds 89,565.37 million shares, accounting for 48.96% of the total issued share capital of 182,945.34 million shares [2] - Baiye Yuan Investment has released a pledge of 19.50 million shares, which represents 2.18% of its holdings and 1.07% of the company's total issued shares [2] - After the release of the pledge, Baiye Yuan Investment has no pledged shares remaining [3] Group 2 - As of the announcement date, the cumulative pledged shares of the controlling shareholder, Baiye Yuan Investment, are zero following the recent release [3] - The company will continue to monitor the pledge and release status of the shares held by its shareholders and will comply with relevant disclosure obligations [3]

Core Points - On September 8, Health元 announced that its controlling shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., will release the pledge of 19.5 million unrestricted circulating shares to the Industrial and Commercial Bank of China, Shenzhen Hongwei Branch, on September 5, 2025 [2] Summary by Category - **Company Announcement** - Health元 disclosed the release of a pledge involving 19.5 million shares [2] - The pledge release has been completed with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [2] - **Shareholder Information** - The controlling shareholder involved in the pledge release is Shenzhen Baiye Yuan Investment Co., Ltd. [2]

截至发稿，健康元市值为245亿元。 每经头条（nbdtoutiao）——"中国真正实现了弯道超车"！从美国回来14年，陈智胜亲历中国创新药大 爆发：以前跨国药企不太信任中国数据，但现在不同了 （记者 胡玲） 每经AI快讯，健康元（SH 600380，收盘价：13.41元）9月8日晚间发布公告称，9月5日，百业源投资将 质押给中国工商银行股份有限公司深圳红围支行的部分无限售流通股1950万股解除质押，并已于中国证 券登记结算有限责任公司上海分公司办理完毕股权质押登记解除手续。经与百业源投资书面确认，本次 百业源投资解除质押的股份，目前暂无后续质押计划。 健康元药业集团股份有限公司控股股东深圳市百业源投资有限公司持有公司无限售流通股约8.96亿股， 占公司已发行总股本（约18.29亿股）48.96%。本次解除质押后，百业源投资无质押股份。 2025年1至6月份，健康元的营业收入构成为：医药制造业占比99.14%，其他业务占比0.86%。 ...

证券代码：600380 证券简称：健康元 公告编号：临 2025-065 健康元药业集团股份有限公司 关于股东部分股权解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●健康元药业集团股份有限公司（以下简称：本公司）控股股东深圳市百业源投 资有限公司（以下简称：百业源投资）持有本公司无限售流通股 89,565.37 万股，占本 公司已发行总股本（182,945.34 万股）48.96%。 健康元药业集团 关于股东部分股权解除质押公告 | | | 占其所 | 占公司 | | | | 剩余被质 | 剩余被质 押股份数 | 剩余被质 押股份数 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 本次解质 | 持股份 | 总股本 | 解质时间 | 持股数量 | 持股 | 押股份数 | 量占其所 | 量占公司 | | | 股份 | | | | | 比例 | | | | | | | 比例 | 比例 | | | | 量 ...

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of Health元, indicating a positive trend in stock price and market activity [1][2][3] - As of September 5, Health元's stock price increased by 2.05% to 13.44 CNY per share, with a total market capitalization of 24.588 billion CNY [1] - Year-to-date, Health元's stock has risen by 21.41%, with notable increases of 8.21% over the last five trading days, 9.62% over the last twenty days, and 17.28% over the last sixty days [1] Group 2 - Health元's main business segments include chemical preparations (47.71%), chemical raw materials and intermediates (31.97%), traditional Chinese medicine preparations (10.28%), diagnostic reagents and equipment (4.74%), health food (3.08%), biological products (1.20%), and others (0.86%) [1] - As of June 30, 2025, Health元 reported a revenue of 7.898 billion CNY, a year-on-year decrease of 4.08%, while net profit attributable to shareholders increased by 1.10% to 785 million CNY [2] - The company has distributed a total of 3.979 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 担保对象及基本情况 ■ ● 累计担保情况 ■ 2025年8月，因日常经营及业务发展需求，健康元药业集团股份有限公司（以下简称：本公司）与平安 银行股份有限公司深圳分行（以下简称：平安银行）签署担保协议，被担保人分别为深圳市海滨制药有 限公司（以下简称：海滨制药）、深圳太太药业有限公司（以下简称：太太药业）、焦作健康元生物制 品有限公司（以下简称：焦作健康元）及健康元海滨药业有限公司（以下简称：健康元海滨），担保金 额分别为人民币20,000.00万元、8,000.00万元、20,000.00万元及10,000.00万元。 本次担保被担保人均为本公司全资子公司，不存在关联担保，本次担保无反担保情况。 （二）内部决策程序 2025年4月7日，本公司召开九届董事会八次会议，审议并通过《关于本公司授信融资及为下属子公司等 提供融资担保的议案》，同意本公司向国家开发银行等银行申请最高不超过人民币共计246.00亿元或等 值外币的授信融资，并同意本公司为深圳市海滨制药有限 ...

Group 1 - The company Health元 announced the signing of a guarantee agreement with Ping An Bank Shenzhen Branch [2] - The guaranteed parties include four wholly-owned subsidiaries of the company: Shenzhen Haibin Pharmaceutical Co., Ltd., Shenzhen Taotai Pharmaceutical Co., Ltd., Jiaozuo Health元 Biological Products Co., Ltd., and Health元 Haibin Pharmaceutical Co., Ltd. [2] - The total guarantee amounts are RMB 200 million, RMB 80 million, RMB 200 million, and RMB 100 million for each respective subsidiary [2]

健康元药业集团 担保进展公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-064 健康元药业集团股份有限公司 关于为控股子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 深圳市海滨制药有限公司 | | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 20,000 万元 | | | | 担保对象一 | 实际为其提供的担保余额 | 万元 22,785.65 | | | | | 是否在前期预计额度内 | 是 □否 | | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | | □不适用：_________ | | 担保对象二 | 被担保人名称 | 深圳太太药业有限公司 | | | | | 本次担保金额 | 8,000 万元 | | | | | 实际为其提供的担保余额 | 万元 0.00 | | | | | 是否在前期预计额度内 | 是 □否 ...